Journal Scans
A Phase 3 Trial of Bevacizumab in Ovarian Cancer
Modest Improvement in Survival With Bevacizumab for Ovarian Cancer
T Perren, A Swart, J Pfisterer, J Ledermann, E Pujade-Lauraine, G Kristensen, M Carey, P Beale, A Cervantes, C Kurzeder, A du Bois, J Sehouli, R Kimmig, A Stahle, F Collinson, S Essapen, C Gourley, A Lortholary, F Selle, M Mirza, A Leminen, M Plante D Stark, W Qian, M Parmar, A Oza
20111129
2011 Dec 29
N Engl J Med
A Phase 3 Trial of Bevacizumab in Ovarian Cancer
N Engl J Med. 2011 Dec 29;365(26):2484-2496, T Perren, A Swart, J Pfisterer, J Ledermann, E Pujade-Lauraine, G Kristensen, M Carey, P Beale, A Cervantes, C Kurzeder, A du Bois, J Sehouli, R Kimmig, A Stahle, F Collinson, S Essapen, C Gourley, A Lortholary, F Selle, M Mirza, A Leminen, M Plante D Stark, W Qian, M Parmar, A Oza
TAKE-HOME MESSAGE
Abstract
SUMMARY
OncologySTAT Editorial Team
The standard treatment for ovarian cancer is typically surgery and platinum-based therapy. Bevacizumab binds to a receptor for vascular endothelial growth factor (VEGF), which is often expressed by ovarian tumor cells. Decreased VEGF expression is associated with reduced tumor vascularization and prolonged survival. This randomized study, the Gynecologic Cancer InterGroup (GCIG) International Collaboration on Ovarian Neoplasms (ICON7) study, evaluated the addition of bevacizumab to standard chemotherapy...
